Click here to read about the launch of T-COVIDTM, an investigational intranasal immune modulator for the treatment of patients with early COVID-19
Click here to read about AdCOVIDTM, a single dose intranasal COVID-19 vaccine candidate, and our collaboration with the University of Alabama at Birmingham.
Our diverse pipeline includes treatments for NASH (ALT-801), chronic Hepatitis B (HepTcell™), and conjugated immunostimulants for the treatment of cancer (ALT-702). In addition, we are developing intranasal vaccine & therapeutic candidates for anthrax, influenza and COVID-19.
ALT-801
ALT-702
NasoVAX™